Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Price to Sales: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Price-to-sales ratio
Latest
98.35
↑ 152% above average
Average (9y)
38.97
Historical baseline
Range
High:98.35
Low:8.13
CAGR
+31.9%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 98.35 | +330.0% |
| 2023 | 22.87 | +153.7% |
| 2022 | 9.01 | -76.0% |
| 2021 | 37.61 | -3.4% |
| 2020 | 38.94 | +47.5% |
| 2019 | 26.40 | -26.5% |
| 2018 | 35.90 | +39.1% |
| 2017 | 25.81 | -70.2% |
| 2016 | 86.65 | +965.7% |
| 2015 | 8.13 | - |